Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Oncolytics Biotech Inc T.ONC

Alternate Symbol(s):  ONCY

Healthcare Biotechnology
Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.


TSX:ONC - Post by User

Oncolytics Biotech Inc > Partnerships...
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(86)
•••
Comment by Quentin30on May 05, 2023 2:50pm
146 Views
Post# 35433598

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Partnerships...

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Partnerships...and yet more attempts to attack me with sarcasm... Great call today... LOL  

As I stated quite some time ago, they won't have OS results until 2024 (as Matt just stated), and they will have to show significantly improved OS over their own data from IND-213 for the payers to consider it worthwhile to include a CPI.

So, it's more than likely that the Phase III for mBC, won't include a checkpoint inhibitor, and that so it has been 5 years of wait...

The only thing we do know is that the patients who were on the safety run-in on the triplet would seem to be alive... so that's 3 of 18..

GLTA, but you don't need any of that in your dinghy do you Angler... muppet...
<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities